NetworkNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Strengthening Leadership Role in Psychedelics Space
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. The company recently made two announcements that show a more immediate response to providing mental health solutions, further strengthening its leadership role in the psychedelic drugs market. First, Mydecine announced that Health Canada had included the dealer’s license, under which the company operates, as a supplier for the Special Access Program (“SAP”). “SAP allows healthcare providers to seek specific drugs normally unavailable for sale in Canada for patients with serious or life-threatening conditions who are not responding to conventional, approved treatment options or whose anticipated treatments are simply not marketed in Canada,” explains a recent article. Under the SAP, Mydecine can manufacture psilocybin and MDMA, commonly known as Ecstasy, at its licensed dealer facility to meet the patients’ needs. Mydecine also partnered with Canadian mental health clinic operator, The Newly Institute Inc., under its Special Access Support and Supply Program (“SASSP”). The program is designed to provide the psychotherapy substances along with packaged investigative brochures, therapy manuals, protocol training, and advisory services.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. The company recently made two announcements that show a more immediate response to providing mental health solutions, further strengthening its leadership role in the psychedelic drugs market. First, Mydecine announced that Health Canada had included the dealer’s license, under which the company operates, as a supplier for the Special Access Program (“SAP”). “SAP allows healthcare providers to seek specific drugs normally unavailable for sale in Canada for patients with serious or life-threatening conditions who are not responding to conventional, approved treatment options or whose anticipated treatments are simply not marketed in Canada,” explains a recent article. Under the SAP, Mydecine can manufacture psilocybin and MDMA, commonly known as Ecstasy, at its licensed dealer facility to meet the patients’ needs. Mydecine also partnered with Canadian mental health clinic operator, The Newly Institute Inc., under its Special Access Support and Supply Program (“SASSP”). The program is designed to provide the psychotherapy substances along with packaged investigative brochures, therapy manuals, protocol training, and advisory services.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
